Renal asymmetric dimethylarginine inhibits fibrosis
Open Access
- 14 August 2020
- journal article
- research article
- Published by Wiley in FEBS Open Bio
- Vol. 10 (10) , 2003-2009
Abstract
Chronic kidney disease (CKD) is a worldwide public health problem that is caused by repeated injuries to the glomerulus or renal tubules. Renal fibrosis commonly accompanies CKD, and it is histologically characterized by excessive deposition of extracellular matrix proteins, such as fibronectin and collagen I, in interstitial areas. Indirect in vivo experimental data suggest that renal asymmetric dimethylarginine (ADMA) exerts antifibrotic activity in CKD. In this study, we aimed to demonstrate that renal ADMA has a direct effect on fibrosis in vivo. Normal saline, ADMA, nonsense control siRNA, Ddah1 siRNA or Ddah2 siRNA was administered into the kidney through the left ureter in a mouse model of unilateral ureteral obstruction (UUO). UUO kidneys were harvested at day 1 or 7. Western blotting was performed to assess the expression of ADMA, DDAH1 and DDAH2 and the expression of fibrotic markers, such as fibronectin, collagen I, α‐smooth muscle actin, phosphorylation of Smad3 and connective tissue growth factor. Masson’s trichrome staining was used to further evaluate renal fibrosis. We observed that intrarenal administration of ADMA increased the renal accumulation of ADMA and attenuated renal fibrosis at days 1 and 7. Knockdown of Ddah1 or Ddah2 increased the amount of ADMA in UUO kidneys and inhibited the expression of fibrotic proteins at days 1 and 7, which was further confirmed by Masson’s staining. Thus, our in vivo data suggest that renal ADMA exerts direct antifibrotic effects in a mouse model of UUO.Keywords
Funding Information
- National Natural Science Foundation of China (81873617)
This publication has 15 references indexed in Scilit:
- Transforming growth factor‐β signalling in renal fibrosis: from Smads to non‐coding RNAsThe Journal of Physiology, 2018
- Mechanisms of Renal FibrosisAnnual Review of Physiology, 2018
- Development of Potent Type I Protein Arginine Methyltransferase (PRMT) Inhibitors of Leukemia Cell ProliferationJournal of Medicinal Chemistry, 2017
- Targeting gene expression to specific cells of kidney tubules in vivo, using adenoviral promoter fragmentsPLOS ONE, 2017
- TGF-β signaling in the kidney: profibrotic and protective effectsAmerican Journal of Physiology-Renal Physiology, 2016
- Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney DamageJournal of the American Society of Nephrology, 2015
- Asymmetric Dimethylarginine and Progression of Chronic Kidney Disease - a One-Year Follow-Up StudyKidney and Blood Pressure Research, 2014
- Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF‐β1 synthesisThe Journal of Pathology, 2010
- Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathyKidney International, 2009
- Dimethylarginine Dimethylaminohydrolase Prevents Progression of Renal Dysfunction by Inhibiting Loss of Peritubular Capillaries and Tubulointerstitial Fibrosis in a Rat Model of Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2007